1. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study. (1st April 2021) Authors: Silverberg, J.I.; Pinter, A.; Alavi, A.; Lynde, C.; Bouaziz, J.‐D.; Wollenberg, A.; Murrell, D.F.; Alpizar, S.; Laquer, V.; Chaouche, K.; Ahmad, F.; Armstrong, J.M.; Piketty, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 7(2021) Page Start: 1562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗